

# Katja Strohfeldt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2480057/publications.pdf>

Version: 2024-02-01

32  
papers

1,641  
citations

257450

24  
h-index

414414

32  
g-index

33  
all docs

33  
docs citations

33  
times ranked

1056  
citing authors

#	ARTICLE	IF	CITATIONS
1	The power of the virtual client “ using problem-based learning as a tool for integration in a pharmaceutical sciences laboratory course. Higher Education Pedagogies, 2019, 4, 462-475.	3.5	0
2	Analysis of Three Epoetin Alpha Products by LC and LC-MS Indicates Differences in Glycosylation Critical Quality Attributes, Including Sialic Acid Content. Analytical Chemistry, 2017, 89, 6455-6462.	6.5	25
3	Ruthenium-conjugated chrysin analogues modulate platelet activity, thrombus formation and haemostasis with enhanced efficacy. Scientific Reports, 2017, 7, 5738.	3.3	41
4	Using Problem-Based Learning in a Chemistry Practical Class for Pharmacy Students and Engaging Them with Feedback. American Journal of Pharmaceutical Education, 2015, 79, 141.	2.1	21
5	Titanocene anticancer complexes and their binding mode of action to human serum albumin: A computational study. Metallomics, 2011, 3, 152.	2.4	18
6	A Model for Self-Directed Problem-Based Learning for Renal Therapeutics. American Journal of Pharmaceutical Education, 2010, 74, 173.	2.1	25
7	Silyl-Modified Analogues of $\pi$ -Tritylpyrrolidine: Synthesis and Applications in Asymmetric Organocatalysis. Chemistry - A European Journal, 2010, 16, 12553-12558.	3.3	37
8	Proliferative and anti-proliferative effects of titanium- and iron-based metallocene anti-cancer drugs. Journal of Organometallic Chemistry, 2009, 694, 874-879.	1.8	43
9	Synthesis and cytotoxicity studies of new dimethylamino-functionalised and aryl-substituted titanocene anti-cancer agents. European Journal of Medicinal Chemistry, 2008, 43, 122-128.	5.5	30
10	Bioorganometallic fulvene-derived titanocene anti-cancer drugs. Chemical Society Reviews, 2008, 37, 1174.	38.1	310
11	Antitumor Activity of Titanocene Y in Xenografted PC3 Tumors in Mice. Letters in Drug Design and Discovery, 2008, 5, 141-144.	0.7	24
12	Antiproliferative activity of Titanocene Y against tumor colony-forming units. Anti-Cancer Drugs, 2007, 18, 317-321.	1.4	46
13	Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice. Anti-Cancer Drugs, 2007, 18, 311-315.	1.4	50
14	The synthesis and cytotoxic evaluation of a series of benzodioxole substituted titanocenes. Applied Organometallic Chemistry, 2007, 21, 57-65.	3.5	27
15	Synthesis and cytotoxicity studies of new dimethylamino-functionalised and heteroaryl-substituted titanocene anti-cancer drugs. Journal of Organometallic Chemistry, 2007, 692, 2153-2159.	1.8	45
16	Synthesis and cytotoxicity studies of new dimethylamino-functionalised and indolyl-substituted titanocene anti-cancer drugs. Transition Metal Chemistry, 2007, 32, 434-441.	1.4	18
17	Proliferative and antiproliferative effects in substituted titanocene anticancer drugs. Transition Metal Chemistry, 2007, 32, 971-980.	1.4	4
18	Crystal Structures of $[\text{PhLi}(\eta^5\text{-sparteine})_2]$ , $[\text{PhOLi}(\eta^5\text{-sparteine})_2]$ , and the Mixed Aggregate $[\text{PhLi}(\eta^5\text{-PhOLi}(\eta^5\text{-sparteine})_2)]$ . Organometallics, 2006, 25, 41-44.	2.3	45

#	ARTICLE	IF	CITATIONS
19	Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice. <i>Anti-Cancer Drugs</i> , 2006, 17, 333-336.	1.4	69
20	Diheteroarylmethyl substituted titanocenes: A novel class of possible anti-cancer drugs. <i>Inorganica Chimica Acta</i> , 2006, 359, 3969-3975.	2.4	30
21	Diarylmethyl substituted titanocenes: Promising anti-cancer drugs. <i>Polyhedron</i> , 2006, 25, 2101-2108.	2.2	32
22	Heteroaryl substituted titanocenes as potential anti-cancer drugs. <i>Journal of Inorganic Biochemistry</i> , 2006, 100, 1479-1486.	3.5	40
23	Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour. <i>European Journal of Pharmacology</i> , 2006, 534, 264-270.	3.5	46
24	Glycol Methyl Ether and Glycol Amine Substituted Titanocenes as Antitumor Agents. <i>European Journal of Inorganic Chemistry</i> , 2006, 2006, 4621-4628.	2.0	23
25	Activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride against tumor colony-forming units. <i>Anti-Cancer Drugs</i> , 2005, 16, 1071-1073.	1.4	45
26	In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes. <i>Anti-Cancer Drugs</i> , 2005, 16, 1091-1098.	1.4	105
27	A trimethoxyphenyl substituted ansa-titanocene: A possible anti-cancer drug. <i>Polyhedron</i> , 2005, 24, 1250-1255.	2.2	40
28	Heteroaryl substituted ansa-titanocene anti-cancer drugs derived from fulvenes and titanium dichloride. <i>Applied Organometallic Chemistry</i> , 2005, 19, 293-300.	3.5	68
29	Novel benzyl substituted titanocene anti-cancer drugs. <i>Journal of Organometallic Chemistry</i> , 2005, 690, 4537-4544.	1.8	118
30	Crystal Structures of (+)-Sparteine Surrogate Adducts of Methyllithium and Phenyllithium. <i>Organometallics</i> , 2004, 23, 5389-5391.	2.3	63
31	[tBuLi⋯(âˆ“)Sparteine]: Molecular Structure of the First Monomeric Butyllithium Compound. <i>Angewandte Chemie - International Edition</i> , 2003, 42, 4531-4533.	13.8	73
32	The Crystal Structures of the Chiral Alkyl lithium Bases [n-BuLi⋅(âˆ“)Sparteine]2 and [Et2O⋅(i-PrLi)2⋅(âˆ“)Sparteine]. <i>Journal of the American Chemical Society</i> , 2003, 125, 13672-13673.	13.7	79